Abstract CT160: The integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily treated patients with T-cell lymphoma
Enrica Marchi(Columbia University Irving Medical Center), Owen A. O’Connor(Virginia Cancer Institute), Ahmed Sawas(Columbia University Irving Medical Center), Karen Khan(Columbia University Irving Medical Center), Luigi Scotto(Columbia University Irving Medical Center), Jennifer Kimberly Lue(Memorial Sloan Kettering Cancer Center), Hye A. Kim(Columbia University Irving Medical Center), Freedy J. Loffredo(Columbia University Irving Medical Center), Nora N Benanni(Mayo Clinic in Arizona), Francesca Montanari(Columbia University Irving Medical Center), Helen Ma(Columbia University Irving Medical Center), Alice T. Jacobs(Columbia University Irving Medical Center), Aishling M. Rada(Columbia University Irving Medical Center), Salvia Salvia(Beth Israel Deaconess Medical Center), Matthew V. Matthew(Columbia University Irving Medical Center), Sandra E. Klein, John Lister(Allegheny Health Network), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Changchun Deng(Columbia University Irving Medical Center), Hye‐Jung Lee(Kyung Hee University), Won-Seog Kim(Samsung Medical Center), Mark A. Francescone(Columbia University Irving Medical Center), Kareema T. Whitfield(Columbia University Irving Medical Center)
Cited by 4
Related Papers
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
|The Lancet Oncology|2010|852
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project
|Blood|2011|431
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma
|New England Journal of Medicine|2022|342